Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Oragenics

Drug Profile

Research programme: antibacterials - Oragenics

Alternative Names: Lantibiotics; MU 1140-S; MU-1140; MU1140 analogs - Oragenics; Mutacin 1140; OG 253; OG 716

Latest Information Update: 29 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Texas A&M University; University of Florida
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Antibacterials; Bacteriocins; Cyclic peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium difficile infections

Most Recent Events

  • 13 Jun 2018 Oragenics announces intention to submit IND application for OG 716 for Clostridium difficile infections in 2019
  • 25 May 2018 Oragenics, Inc. and Texas A&M University System has patent protection for variants of the lantibiotic MU 1140 and other lantibiotics in the US
  • 27 Feb 2017 Oragenics has a patent pending for lantibiotic MU 1140 and its homologues in USA (Oragenics 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top